Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abciximab readministration.

James L Orford1, David R Holmes

  • 1Division of Internal Medicine and Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.

Reviews in Cardiovascular Medicine
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Art and science.

Journal of the American College of Cardiology·2014
Same author

Fundamental concepts of effective troponin use: important principles for internists.

The American journal of medicine·2014
Same author

A prospective randomized controlled study of erythromycin on gastric and small intestinal distention: implications for MR enterography.

European journal of radiology·2014
Same author

Delayed transcatheter heart valve migration and failure.

JACC. Cardiovascular imaging·2014
Same author

Aortic valve replacement for severe aortic valve stenosis in the nonagenarian patient.

The Annals of thoracic surgery·2014
Same author

Snake eyes.

Journal of the American College of Cardiology·2014
Same journal

The Influence of Congenital Heart Defect Repair Through a Right Subaxillary Thoracotomy on Postoperative Pulmonary Function and Prognosis in Small Infants.

Reviews in cardiovascular medicine·2026
Same journal

Left Ventricular Hypertrabeculation: Historical Evolution, Diagnostic Pitfalls, and a Pragmatic Clinical Approach.

Reviews in cardiovascular medicine·2026
Same journal

Study on the Role and Mechanism of γδ T Cells in Atherosclerosis Under a High-Fat Diet.

Reviews in cardiovascular medicine·2026
Same journal

The Role of Stress Granules in Cardiovascular Diseases.

Reviews in cardiovascular medicine·2026
Same journal

Computed Tomography-Based Radiomics Provides New Insights Into Associations Between Pericoronary Fat Characteristics and Low-Density Lipoprotein Cholesterol.

Reviews in cardiovascular medicine·2026
Same journal

Association of Triglyceride-Glucose Index With In-Hospital Malignant Arrhythmias in Older Patients With Diabetes Mellitus and Left Ventricular Aneurysm: A Retrospective Study.

Reviews in cardiovascular medicine·2026
See all related articles

Readministration of abciximab following percutaneous coronary intervention (PCI) is safe and effective. While overall thrombocytopenia incidence is unchanged, profound thrombocytopenia occurred more frequently with repeat abciximab use.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Glycoprotein IIb/IIIa receptor inhibitors, such as abciximab, improve outcomes after percutaneous coronary intervention (PCI), reducing myocardial necrosis.
  • Concerns exist regarding abciximab's safety and efficacy upon repeat administration, including anaphylaxis, thrombocytopenia, and diminished clinical benefit.
  • Previous studies show abciximab offers mortality advantages in diabetic patients undergoing PCI.

Purpose of the Study:

  • To evaluate the safety and clinical efficacy of repeat abciximab administration in patients undergoing PCI.
  • To assess the incidence of thrombocytopenia following repeat abciximab treatment compared to historical controls.

Main Methods:

  • A prospective, phase IV, multicenter registry (ReoPro Readministration Registry) enrolled 500 patients.

Related Experiment Videos

  • Patients received abciximab for PCI at least 7 days after a prior abciximab treatment.
  • Outcomes, including thrombocytopenia, were compared with historical control data from initial abciximab administration trials.

    • Main Results:

    • Abciximab readministration was found to be safe and clinically effective in patients undergoing PCI.
    • The overall incidence of thrombocytopenia did not significantly increase compared to historical controls.
    • A notable increase in the frequency of profound thrombocytopenia was observed with repeat abciximab administration.

    Conclusions:

    • Repeat administration of abciximab following PCI is a safe and effective therapeutic strategy.
    • While overall thrombocytopenia rates remain stable, clinicians should be aware of a potential shift towards profound thrombocytopenia with repeated use.
    • Further investigation into the mechanisms and management of profound thrombocytopenia in this context is warranted.